Suppr超能文献

G蛋白偶联受体作为药物研发靶点的未来。

The future of G protein-coupled receptors as targets in drug discovery.

作者信息

Lundstrom Kenneth

机构信息

BioXtal, Chemin des Croisettes 22, CH-1066 Epalinges, Switzerland.

出版信息

IDrugs. 2005 Nov;8(11):909-13.

Abstract

G protein-coupled receptors (GPCRs) represent the most abundant drug targets today. A large number of GPCR-based drugs have already been developed for a variety of indications in human disease. However, orphan receptors with unidentified ligands serve as potential targets still to be explored. Moreover, research on the interaction of GPCRs with different molecules in the signal transduction pathways, and further studies on receptor dimerization may also lead to the discovery of new drugs. Structure-based drug design will eventually play a key role in generating better and more selective drugs more rapidly when high-resolution structures of GPCRs can be provided by expression, purification and crystallography technologies.

摘要

G蛋白偶联受体(GPCRs)是目前最为丰富的药物靶点。大量基于GPCR的药物已被开发用于治疗人类疾病的各种适应症。然而,配体未明的孤儿受体仍是有待探索的潜在靶点。此外,对GPCRs在信号转导途径中与不同分子相互作用的研究,以及对受体二聚化的进一步研究,也可能会带来新药的发现。当通过表达、纯化和晶体学技术能够提供GPCRs的高分辨率结构时,基于结构的药物设计最终将在更快速地研发出更好、更具选择性的药物方面发挥关键作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验